Redeye reiterates our positive view of Annexin Pharmaceuticals and lead candidate ANXV in retinal vein occlusion (RVO) following today’s announcement that the company has had successful meetings with a selection of regulatory authorities on the path to approval for ANXV (now in phase I). Given the innovative nature of Annexin’s treatment approach, we are pleased that regulators and Annexin are aligned at this stage. Our base case of SEK 4 offers a significant upside (100%) from today’s levels.